PULM vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 12, 2026

PULM

35.8
AI Score
VS
CBIO Wins

CBIO

41.1
AI Score

Investment Advisor Scores

PULM

36score
Recommendation
AVOID NEW MONEY

CBIO

41score
Recommendation
HOLD

Detailed Metrics Comparison

Metric PULM CBIO Winner
Forward P/E 0.0 -5.4 Tie
PEG Ratio 0.0 0.0 Tie
Revenue Growth -99.9% 0.0% CBIO
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 35.8/100 41.1/100 CBIO
Profit Margin 0.0% 0.0% Tie
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY HOLD CBIO

Relative Price Performance (Last 90 Days)

PULM 1M: -8.5% · 3M: -17.3% CBIO 1M: +13.4% · 3M: -19.1%

Current Technical Phase

PULM

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 40

RSI (14): 40.3 · Price: $1.29

CBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 52

RSI (14): 52.4 · Price: $14.15

Fundamentals Snapshot

Metric PULM CBIO
Market Cap — —
Forward P/E 0.0 -5.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -99.9% 0.0%
Gross Margin -1266.7% 100.0%
Operating Margin 0.0% -14.3%
EPS -1.10 -7.63
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, CBIO is currently the stronger investment candidate with a higher AI composite score (41.1/100 vs. 35.8/100), supported by its current technical phase (PULM: Markdown, CBIO: Neutral) and fundamental profile.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.